Clinical trial
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have…
NCT00053638 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00053638 |
|---|---|
| Title | A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy |
| Official title | A Phase III, Randomized, Open-label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-dose Combination Tablet as a Once-daily Regimen in Antiretroviral-naive HIV-1 Infected Subjects. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | efavirenz, tenofovir, abacavir/lamivudine |
| Enrollment | 345 |
| Start date | Feb 1, 2003 |
| Primary completion | Oct 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Feb 5, 2003 |
| Last update posted | Oct 4, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: